We are live on ! Find out more
NVS icon

Novartis

1,183 hedge funds and large institutions have $14.9B invested in Novartis in 2022 Q4 according to their latest regulatory filings, with 173 funds opening new positions, 298 increasing their positions, 493 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more first-time investments, than exits

New positions opened: 173 | Existing positions closed: 60

134% more call options, than puts

Call options by funds: $798M | Put options by funds: $341M

30% more funds holding in top 10

Funds holding in top 10: 10 → 13 (+3)

9% more funds holding

Funds holding: 1,089 → 1,183 (+94)

0.55% less ownership

Funds ownership: 8.23% → 7.68% (-0.55%)

40% less repeat investments, than reductions

Existing positions increased: 298 | Existing positions reduced: 493

47% less capital inflows, than outflows

Capital inflows: $722M | Capital outflows: $1.35B

Holders
1,183
Holders Change
+94
Holders Change %
+8.63%
% of All Funds
18.94%
Holding in Top 10
13
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+30%
% of All Funds
0.21%
New
173
Increased
298
Reduced
493
Closed
60
Calls
$798​M
Puts
$341​M
Net Calls
+$456​M
Net Calls Change
+$220​M

NVS Hedge Fund Activity: Q4 2022 in Review

1,183 of the 6,245 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q4 2022, worth a combined $14.9B — up 9.4% from $13.7B a quarter earlier.

Buyers outnumbered sellers: 173 funds opened new NVS positions and 60 closed out — a net gain of 113 holders — while 298 added to existing stakes and 493 trimmed.

The largest buyer was Arrowstreet Capital, adding an estimated $210M. The largest seller was Loomis, Sayles & Company, cutting an estimated $336M.

  • 1,183 institutional investors held Novartis (NVS) as of Q4 2022, up from 1,089 in Q3 2022.
  • Funds reported $14.9B of Novartis stock for Q4 2022, up 9.4% quarter-over-quarter.
  • 173 funds opened new Novartis positions in Q4 2022 and 60 closed out, a net change of +113 holders.
  • The largest Novartis buyer in Q4 2022 was Arrowstreet Capital, an estimated $210M added.
  • The largest Novartis seller in Q4 2022 was Loomis, Sayles & Company, an estimated $336M sold.

Based on aggregated 13F filings for Q4 2022.